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ABSTRACT

change in angina at 16 weeks as assessed by the
Seattle Angina Questionnaire (SAQ).

Introduction: We aimed to assess if ranolazine
would improve angina symptoms among

Results: Between September 2014 and January
2016, 25 subjects were randomized to

patients

myocardial

ranolazine versus 25 to placebo. The most

chronic

common reason for eligibility was CTO (72%),
while the remainder had myocardial ischemia

stable angina and at least one coronary
stenosis with fractional flow reserve (FFR)

documented by low FFR. The mean FFR was
0.57 ± 0.12. Sixty-eight percent of subjects were

B0.80 or at least one chronic total occlusion

on two or more anti-angina medications at

(CTO) without attempted revascularization.
Subjects were randomized to oral ranolazine

baseline. Study medication was discontinued in
32% (eight of 25) of the ranolazine group versus

500 mg twice daily for 1 week, then ranolazine
1000 mg twice daily for 15 weeks versus

36% (nine of 25) of the placebo group. By
intention-to-treat, 46 subjects had baseline and

matching placebo. The primary end point was

follow-up SAQ data completed. Ranolazine was

with

ischemia.
Methods: Eligible

documented
subjects

had
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not associated with an improvement in angina
compared with placebo at 16 weeks. The results
were similar among 33 subjects that completed
study
medication.
The
incidence
of
ischemia-driven

hospitalization

or

catheterization was 12% (three of 25) of the
ranolazine group versus 20% (five of 25) in the
placebo group (p[0.05).
Conclusions: In
subjects

with

chronic

stable angina and documented myocardial
ischemia, ranolazine did not improve angina
symptoms at 16 weeks.
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Funding: Gilead.

documented myocardial ischemia, defined by

Clinical trial registration: The study was
registered at ClinicalTrials.gov (NCT02265796).

either low fractional flow reserve (FFR) or
presence of a chronic total occlusion (CTO),
and who did not undergo revascularization.

Keywords: Angina; Coronary artery disease;
Ranolazine;

Randomized

controlled

trial;

Revascularization; Stable

METHODS
Study Design and Selection Criteria

INTRODUCTION
This was a randomized single-center trial that
Revascularization by percutaneous coronary
intervention (PCI) or coronary artery bypass
grafting (CABG) is feasible for the majority of
patients with symptomatic ischemic heart
disease, with resolution of their symptoms.
However, many of these patients continue to
have angina symptoms due to residual
ischemia, which can result in repeat
revascularizations and adverse cardiovascular
events [1, 2]. Ranolazine is an anti-ischemia/
anti-angina medication that inhibits the late
sodium current but does not affect the heart
rate or blood pressure [3]. Ranolazine was

enrolled subjects at least 18 years of age who
were referred for catheterization for evaluation
of angina, fatigue, or shortness of breath. This
investigator initiated study was sponsored by
Gilead Sciences. In addition to symptoms
compatible with chronic stable angina, we
required the following: (1) at least one
borderline coronary stenosis with documented
myocardial ischemia by FFR (B0.8) or at least
one

CTO,

and

(2)

no

attempted

revascularization of the ischemic artery. CTO
was defined as an occlusion in a C2 mm

recurrent

epicardial coronary artery in which distal flow
was provided by antegrade or retrograde

ischemia among patients with acute coronary
syndrome and history of angina [4]. In the

collaterals. An occlusion which was supplied
by a patent bypass graft was not considered a

Ranolazine
for
Incomplete
Vessel
Revascularization Post-Percutaneous Coronary

CTO. The assumed FFR value of a CTO was 0.5

associated

with

a

reduction

in

multicenter

[8]. The decision not to revascularize an
ischemic lesion was left to individual operator

randomized trial, ranolazine failed to reduce
ischemia-driven
hospitalization
or

discretion, but included the following reasons:
patient preference for initial medical therapy,

ischemia-driven revascularization in chronic
angina
patients
with
incomplete

lesion characteristics that increased the risk for

Intervention

revascularization
revascularization

(RIVER-PCI)

[5].

However,
was

incomplete
assessed

angiographically, which is known to only
modestly correlate with underlying myocardial
ischemia [6, 7].
Therefore, we aimed to assess whether
ranolazine would improve angina symptoms
and subjective well-being among patients with

restenosis (diffuse disease in a small vessel), or
characteristics that increased the risk for
procedural complication (severe calcification,
excessive angulation/tortuosity, or inability to
protect a bifurcation lesion). The following
patients
were
excluded;
coronary
revascularization within the index procedure
or planned in the next month, acute coronary
syndrome or cardiogenic shock, use of strong

Cardiol Ther (2017) 6:81–88

83

inhibitors of CYP3A, use of inducers of CYP3A,

significance level was defined as p\0.05. All

liver

statistical analysis was conducted using SAS 9.4

cirrhosis,

severe

renal

insufficiency
2

(creatinine clearance \30 ml/min/1.73 m ), or
baseline corrected QT interval [500 ms.

(SAS Institute, Inc., Cary, NC, USA). We
conducted power analysis based on the SAQ

Randomization

results measured in a previous study [11]. We
hypothesized that patients at baseline would
have a mean ± SD of 53 ± 23 for physical

Eligible subjects were randomly assigned to
receive either oral ranolazine 500 mg twice

limitation, 64 ± 28 for angina frequency,
53 ± 28 for angina stability, 79 ± 19 for

daily for 1 week, then ranolazine 1000 mg
twice daily for 15 weeks vs. matching placebo

treatment satisfaction, and 50 ± 22 for disease
perception [2]. Assuming a 20% change after

(one tablet twice daily for 1 week, then two
tablets twice daily for 15 weeks). Randomization

follow up 16 weeks, it was estimated that 14-53

was performed with Excel 2010 utilizing the

patients in each domain would give an 80% of
power to detect a statistically significant

RAND function. A sample size of 50 was
randomized using a simple schema with two

difference between baseline and follow up
(a = 0.05).

levels representing treatment assignments
without stratification. Block size was set at 10.

Safety and Ethics

Study investigator, patient, and research team
were blinded to treatment assignment. The
treatment assignment code was kept by

Institutional review board approval was
obtained from the University of Florida. The

research pharmacy.

study was registered at ClinicalTrials.gov
(NCT02265796). An independent data safety

Endpoints and Statistics

monitor periodically reviewed adverse events to
evaluate if there were any potential safety

The primary end point was change in angina
from baseline to 16 weeks as assessed by the

issues.

All

procedures

followed

were

in

[9].

accordance with the ethical standards of the
responsible
committee
on
human

Secondary endpoints included subjective
well-being, in which subjects were asked, ‘‘in

experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as

the last month, how would you rate your
overall feeling of well-being (poor, fair, good,

revised in 2013. Informed consent was obtained

Seattle

Angina

Questionnaire

(SAQ)

or excellent) [10].’’ Lastly, the incidence of

from all patients for being included in the
study.

ischemia-driven
catheterization

RESULTS

hospitalization
or
was
assessed.
Baseline

characteristics were described as frequencies
for categorical variables and means, with
standard deviations, for continuous variables.
2

Student’s t test, and the v test were used for the
comparison of the continuous and categorical
variables, respectively. Paired t test was used to
compare the changes within a group. Statistical

Between September 2014 and January 2016, 25
subjects were randomized to ranolazine versus
25 to placebo. Follow-up SAQ was not obtained
in four subjects. This was due to one death, and
two study withdrawals in the ranolazine group
and one study withdrawal in the placebo group.

Cardiol Ther (2017) 6:81–88

84

Table 1 Baseline characteristics
Ranolazine
(n 5 25)

medication (i.e., primidone), and one patient
stopped the medication for no clear reason.

Placebo
(n 5 25)

p value

100

100

[0.99

16 weeks. Three out of five SAQ domains
improved from baseline to follow-up in both

Hyperlipidemia

64

67

0.83

groups (Angina Stability, Angina Frequency,

Diabetes mellitus

55

63

0.58

On insulin

18

29

0.50

and Quality of Life); however, there was no
difference between the treatment and placebo

h/o PCI

77

54

0.10

h/o CABG

32

25

0.61

By intention-to-treat, 46 subjects had
baseline and follow-up SAQ data completed at

Past medical history (%)
Hypertension

CABG coronary artery bypass grafting, h/o history of, PCI
percutaneous coronary intervention

The

most

common

reason

for

anatomic

eligibility was chronic total occlusion that was

groups (Table 2). There was no within-group
change in Physical Limitation, or Treatment
Satisfaction (Table 2). There was also no change
in subjective well-being over the follow-up
period (Table 3). The results were similar
among 33 subjects that completed study
medication.
At

16 weeks,

the

incidence

of

present in 72%, while the remainder had
myocardial ischemia documented by FFR

ischemia-driven
hospitalization
or
catheterization was three out of 25 in the

(mean FFR value was 0.57 ± 0.12). The mean
age was 67 years ± 9 years, mean left ventricular

ranolazine group versus five out of 25 in the
placebo group (p[0.05).

ejection fraction was 53 ± 11%, and mean left
ventricular end diastolic pressure was 12
± 5 mmHg. Sixty-eight percent of subjects

DISCUSSION

were on two or more anti-angina therapies at
baseline (80% on a beta-blocker, 60% on a

Among patients with documented myocardial

long-acting nitrate, and 35% on a calcium

ischemia (mean FFR = 0.57) and no attempted
revascularization, ranolazine failed to improve

channel antagonist). Additional baseline
characteristics are provided in Table 1.

angina symptoms or subjective well-being
compared with placebo. Findings were the

Discontinuation
occurred in 32%

same by intention-to-treat analysis and also

of study medication
(eight of 25) of the

ranolazine group at a mean of 55 ± 46 days

among the cohort that completed their
treatment assignment. As a secondary

(median, 46 days) versus 36% (nine of 25) of the
placebo group at a mean of 31 ± 27 days

outcome,
incidence
of
ischemia-driven
hospitalization or catheterization was similar

(median, 31 days) (p[0.05). Dizziness or
impaired memory was reported in 20% (five of

between treatment groups. Discontinuation of

25) of the ranolazine group versus 12% (three of
25) in the placebo group (p[0.05). Other

study medication was high, but similar
between groups and there was no appreciable

the

difference in adverse events between treatment
groups.

ranolazine arm included: tiredness (one
patient), started on another QT prolonging

Lack of benefit could be due to good
background medical therapy (68% on two or

reasons

for

drug

discontinuation

in
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Table 2 Change in Seattle Angina Questionnaire from baseline to 16 weeks
Seattle Angina Ranolazine (n 5 22)
Questionnaire
domains

Placebo (n 5 24)

Intention-to-treat
analysis, between-group
difference (n 5 46)

On treatment analysis,
between-group
difference (n 5 33)

p = 0.12

p = 0.13

p = 0.94

p = 0.78

p = 0.98

p = 0.66

p = 0.89

p = 0.70

p = 0.76

p = 0.74

Physical limitation
Baseline

48 ± 25

50 ± 20

16 weeks

40 ± 19

60 ± 24

Change*

-7 ± 27 (p = 0.31)

6 ± 20 (p = 0.22)

Baseline

39 ± 28

37 ± 28

16 weeks

58 ± 26

55 ± 27

19 ± 36 (p = 0.025)

18 ± 32
(p = 0.0093)

Angina stability

Change

*

Angina frequency
Baseline

65 ± 24

64 ± 23

16 weeks

81 ± 23

80 ± 24

Change*

16 ± 36 (p = 0.055)

15 ± 27
(p = 0.0095)

Treatment satisfaction
Baseline

80 ± 19

85 ± 18

16 weeks

77 ± 26

82 ± 22

-4 ± 26 (p = 0.52)

-3 ± 26 (p = 0.64)

Baseline

37 ± 24

45 ± 27

16 weeks

56 ± 29

63 ± 28

Change

*

Quality of life

Change

*

21 ± 32 (p = 0.0067) 18 ± 31
(p = 0.0083)

*Within-group difference

more anti-angina therapies at baseline) versus

Inadequate power also remains a possible

relative ineffectiveness of ranolazine as an
anti-angina agent [12]. There was also a strong

explanation for the lack of association
between ranolazine and angina measures.

placebo

subjects

While anti-angina therapy is an important

randomized to placebo experienced a six-unit
improvement in angina stability, a 15-unit

treatment strategy among patients with
ischemic heart disease [13], PCI has been

improvement in angina frequency, and an
18-unit improvement in quality of life.

shown to provide greater angina relief
compared with optimal medical therapy [14].

effect.

For

example,
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Table 3 Change in subjective well-being from baseline to 16 weeks
Ranolazine (n 5 22)

Placebo (n 5 24)

Baseline

40

24

16 weeks

50

42

10 (p = 0.50)

18 (p = 0.19)

Baseline

56

68

16 weeks

46

42

Change*

-11 (p = 0.48)

-26 (p = 0.067)

Subjective well-being
categories

Between-group
difference (p value)

Excellent/good (%)

Change

*

0.58

Fair/poor (%)

0.80

*Within-group difference
At the time this study was designed, RIVER-PCI

the rate of discontinuation was the same

was actively enrolling. Our findings were similar to
the overall negative findings of the later reported

between study drug and placebo. The small
sample size might have decreased to study

RIVER-PCI trial [5]. In addition, among 864

power

patients enrolled with a chronic total occlusion
in the RIVER-PCI trial, ischemia-driven

differences between both groups. Additionally,
there was no difference in the intention-to-treat

revascularization
or
ischemia-driven
hospitalization occurred in 27% of the ranolazine

analysis versus the on-treatment analysis.

group versus 30% of the placebo group (HR = 0.95,

CONCLUSIONS

95% CI 0.74–1.22, Pinteraction = 0.91) [5]. This
group is most similar to the characteristics of our
study participants. There was also no
improvement in angina burden from ranolazine
versus placebo in the overall RIVER-PCI trial [15].
This study was intended to be a pilot study to
investigate for any potential benefit in this patient
population, and in so doing to estimate the sample
size needed for a definitive study. However, given

to

detect

statistically

significant

In conclusion, among subjects with chronic
stable angina and documented myocardial
ischemia, ranolazine did not improve the
frequency of angina or subjective well-being at
16 weeks.
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